Sangamo BioSciences | SGMO - Ordinary Share Capital


Sangamo BioSciences reported $1.77M in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.38M 172K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
Amgen USD 541M 1000K Jun/2026
Bayer EUR 982.42M 0 Jun/2026
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Cipla INR 807.78M 17K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1000 Mar/2026
CSL USD 482.13M 93.87M Dec/2025
Gilead Sciences USD 1.24B 1000K Jun/2026
GlaxoSmithKline GBP 4.08B 20.6M Jun/2026
Grifols EUR 680.58M 846.11K Dec/2025
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
J&J USD 2.41B 1.35M Mar/2026
Karyopharm Therapeutics USD 22.54M 4.23M Mar/2026
Merck USD 2.47B 4.93M Mar/2026
Novartis USD 1.9B 7.38M Jun/2026
Omeros USD 611K 17K Dec/2023
Pfizer USD 5.7B 0 Jun/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Tectonic Therapeutic USD 18.83M 92.19K Mar/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026